UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________
FORM 8-K
_____________
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): December 11, 2017
 
TG Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction
of Incorporation)
001-32639
(Commission File Number)
 
36-3898269
(IRS Employer Identification No.)
 
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address of Principal Executive Offices)
 
(212) 554-4484
(Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 ☐

Written communications pursuant to Rule 425 under the Securities Act.
 ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
 ☐

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
 ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
 
 
 
Item 8.01. Other Events.
 
   On December 11, 2017, TG Therapeutics, Inc. (the “Company”) issued a press release announcing clinical and preclinical data presented involving the Company’s lead compounds, TGR-1202 (umbralisib), the Company's once-daily PI3K delta inhibitor, and TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, at the 59th American Society of Hematology (ASH) annual meeting, being held at the Georgia World Congress Center in Atlanta, Georgia. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.
 
Item 9.01 Financial Statements And Exhibits.
 
(d) Exhibits.
 
99.1  Press Release, dated December 11, 2017.
 
-2-
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
TG Therapeutics, Inc.
 
(Registrant)
 
 
 
 
 
 
Date: December 11, 2017
 

By: /s/ Sean A. Power             
 
Sean A. Power
 
Chief Financial Officer
 
 
 
 
 
-3-